Reversible Intrapulmonary Vascular Dilatation in a Patient Treated With Luspatercept for Myelodysplastic Syndrome
CHEST · 2026
DOI: 10.1016/j.chest.2026.02.012 ↗Kurz gefasst
Fallbericht in der Zeitschrift CHEST, 2026. Verfasst von Fatema Al Lawati und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology and Sleep Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Activin Receptors, Type II, Recombinant Fusion Proteins, Hypoxia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A 70-year-old man with transfusion-dependent myelodysplastic syndrome was treated with luspatercept. Nine months into treatment and 2 months after dose increase, he developed new hypoxemia with a room air resting oxygen saturation of 88%. He was admitted, requiring up to 90% Fio2 by high-flow nasal cannula to maintain saturations ≥ 92%. CT scan demonstrated stable mild probable usual interstitial pneumonia, without ground-glass, pulmonary embolism, or arteriovenous malformation. Agitated saline contrast-enhanced echocardiogram was late positive, consistent with intrapulmonary shunt. Macroaggregated albumin (MAA) shunt scintigraphy demonstrated a shunt of 7.5%. Extensive investigations ruled out congenital portosystemic shunt and hepatopulmonary syndrome. We diagnosed hypoxemia from intrapulmonary vascular dilatation (IPVD), with luspatercept as a possible cause. Oxygen requirements improved, and supplemental oxygen was discontinued by 7 weeks after cessation. Repeat MAA 10 weeks after cessation confirmed shunt resolution (3.6% shunt). This case of reversible IPVD attributable to luspatercept highlights important monitoring implications in treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respirology and Sleep Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada.
- Division of Respirology, Department of Medicine, Li Ka Shing Knowledge Institute and St. Michael's Hospital, Toronto, ON, Canada.
- Division of Respirology, Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.
- Division of Hematology, Department of Medicine Queen's University, Queen's University, Kingston, ON, Canada.
- Division of Cardiology, Department of Medicine, Queen's University, Kingston, ON, Canada.
- Division of Respirology and Sleep Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada. Electronic address: gcd1@queensu.ca.
Zitieren
APA
Al Lawati, F., Gupta, S., Faughnan, M. E., Granton, J., Climans, T., Thakrar, A., & Digby, G. C. (2026). Reversible Intrapulmonary Vascular Dilatation in a Patient Treated With Luspatercept for Myelodysplastic Syndrome. CHEST. https://doi.org/10.1016/j.chest.2026.02.012
Vancouver
Al Lawati F, Gupta S, Faughnan ME, Granton J, Climans T, Thakrar A, et al. Reversible Intrapulmonary Vascular Dilatation in a Patient Treated With Luspatercept for Myelodysplastic Syndrome. CHEST. 2026. doi:10.1016/j.chest.2026.02.012
BibTeX
@article{AlLawati2026,
author = {Al Lawati, Fatema and Gupta, Samir and Faughnan, Marie E and Granton, John and Climans, Troy and Thakrar, Amar and Digby, Geneviève C},
title = {Reversible Intrapulmonary Vascular Dilatation in a Patient Treated With Luspatercept for Myelodysplastic Syndrome},
journal = {CHEST},
year = {2026},
doi = {10.1016/j.chest.2026.02.012}
}
EUVIMED